Product image of Mivacron (Mivacurium) supplied by GNH India

Mivacron

Active Ingredient:
Mivacurium
Origin:
EU

Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a neuromuscular blocking agent presented as a sterile injectable solution for intravenous use. It provides short‑acting skeletal muscle relaxation to facilitate endotracheal intubation and to support surgical procedures.
GNH India supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aspen Pharma Trading Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mivacurium is a neuromuscular blocking agent used to produce rapid, short‑duration muscle relaxation in peri‑operative settings.

  • Facilitation of endotracheal intubation: provides brief muscle relaxation that allows safe placement of the airway tube.
  • Muscle relaxation during surgery: enables controlled skeletal muscle relaxation for operative procedures.
  • Adjunct to general anesthesia: supports induction of anesthesia by delivering rapid neuromuscular blockade.

How It Works

  • Mivacurium acts as a competitive antagonist at nicotinic acetylcholine receptors located on the motor end‑plate of skeletal muscle. By blocking acetylcholine binding, it prevents depolarization of the muscle membrane, resulting in a reversible loss of muscle tone and temporary paralysis until the drug is hydrolyzed by plasma pseudocholinesterase.

Side Effects

Mivacurium may cause a range of adverse reactions, most of which are related to its histamine‑releasing properties or to prolonged neuromuscular blockade.

Common Side Effects

  • Flushing: transient redness of the skin due to histamine release.
  • Transient hypotension: brief drop in blood pressure, usually self‑limiting.
  • Bronchospasm: airway narrowing that may cause wheezing, especially in reactive airway disease.
  • Tachycardia: mild increase in heart rate.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate intervention.
  • Prolonged neuromuscular blockade: especially in patients with pseudocholinesterase deficiency.
  • Hyperkalemia: elevated potassium levels in susceptible individuals.
  • Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.

Precautions & Warnings

When using Mivacron, clinicians should observe several safety measures to minimize risks.

  • Assess pseudocholinesterase activity: deficiency can extend drug effect.
  • Avoid in patients with known hypersensitivity to mivacurium or related compounds.
  • Monitor cardiovascular status: histamine release may cause hypotension.
  • Use caution in asthma or reactive airway disease: risk of bronchospasm.
  • Evaluate concomitant medications that may potentiate neuromuscular blockade.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular function.

Major Interactions (Avoid)

  • Concurrent use of other neuromuscular blocking agents: additive paralysis.
  • Anticholinesterase drugs administered before full recovery: may potentiate block.
  • Magnesium sulfate: enhances neuromuscular blockade.

Moderate Interactions (Monitor Closely)

  • Inhalational anesthetics: may increase duration of muscle relaxation.
  • Beta‑adrenergic blockers: can affect hemodynamic response during administration.

Frequently Asked Questions

Mivacron contains the neuromuscular blocking agent mivacurium and is used to produce short‑acting skeletal muscle relaxation. It facilitates endotracheal intubation and provides controlled muscle relaxation during surgical procedures under general anesthesia.

Mivacurium competitively blocks nicotinic acetylcholine receptors at the motor end‑plate, preventing acetylcholine from triggering muscle depolarization. This results in a reversible loss of muscle tone until the drug is hydrolyzed by plasma pseudocholinesterase.

The dose of Mivacron is determined by the prescribing clinician based on patient weight, the required depth of muscle relaxation, and the specific surgical or procedural context. Exact dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for mivacurium in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To request Mivacron, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mivacron is a short‑acting, non‑depolarizing blocker that is rapidly hydrolyzed by pseudocholinesterase, offering a quicker recovery than longer‑acting agents such as rocuronium. Its histamine‑release profile may be more pronounced than some alternatives, requiring careful monitoring in sensitive patients.

Mivacron should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging until use to maintain sterility and potency.

Mivacron is administered intravenously as a sterile solution. It is typically given as a bolus injection under the supervision of an anesthesiologist, with dosage adjusted to achieve the desired level of neuromuscular blockade.

Serious risks include anaphylactic reactions, prolonged neuromuscular blockade in patients with pseudocholinesterase deficiency, severe bronchospasm, and cardiac arrhythmias. Prompt recognition and appropriate emergency measures are essential if these events occur.

Mivacron should be avoided in patients with known hypersensitivity to mivacurium or related compounds, those with severe pseudocholinesterase deficiency, and individuals with uncontrolled asthma or other reactive airway diseases where bronchospasm risk is high.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mivacurium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT